| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-11-13 | NBTXR3 | soft tissue sarcoma | 2-3 | Nanobiotix (France) | Cancer - Oncology |
| 2015-11-12 | avapritinib (BLU-285) | acute myeloid leukemia (AML) | preclinical | Blueprint Medicines (USA - MA) | Cancer - Oncology |
| 2015-11-12 | atezolizumab (MPDL3280A) | triple-negative breast cancer (TNBC) | 1b | Roche (Switzerland) | Cancer - Oncology |
| 2015-11-12 | Winlevi™ (ortexolone 17?-Propionate (CB-03-01) 1% Cream) | facial acne vulgaris | 3 | Cassiopea (Switzerland) | Dermatological diseases |
| 2015-11-12 | lirilumab and nivolumab alone or in combination with azacitidine | myelodysplastic syndrome (MDS) | 2 | BMS (USA - NY) | Cancer - Oncology |
| 2015-11-11 | SPK-TPP1 | Batten disease | preclinical | Spark Therapeutics (USA - PA) | Rare diseases - Genetic diseases - Neurological diseases - Neurodegenerative diseases |
| 2015-11-11 | ND0612H (levodopa and carbidopa administered through a pump patch) | Parkinson's disease | 2 | NeuroDerm (Israel) | Neurodegenerative diseases - CNS diseases |
| 2015-11-11 | ND0612L (subcutaneous doses of liquid levodopa/carbidopa) | Parkinson\'s disease | 2a | Neuroderm (Israel) | Neurodegenerative diseases |
| 2015-11-10 | lomitapide | homozygous familial hypercholesterolemia | Aegerion Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases - Metabolic diseases | |
| 2015-11-10 | alirocumab (SAR236553/REGN727) | patients with heterozygous familial hypercholesterolemia (heFH) patients with primary hypercholesterolemia with elevated LDL-C |
3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases - Genetic diseases - Rare diseases |
| 2015-11-09 | Small Molecule Assisted Receptor Targeting (SMART™) platform | Warp Drive Bio (USA - MA) | Cancer - Oncology | ||
| 2015-11-09 | axicabtagene ciloleucel (KTE-C19) (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) | relapsed/refractory mantle cell lymphoma | 2 | Kite Pharma (USA - CA) | Cancer - Oncology - Rare diseases |
| 2015-11-09 | Alzheimer's disease | Teva Pharmaceutical Industries (Israel) University College London (UK) | Neurodegenerative diseases | ||
| 2015-11-09 | CHS-0214 (investigational etanercept biosimilar) | plaque psoriasis | 3 | Coherus Biosciences (USA - CA) Baxalta (USA - IL) | Autoimmune diseases - Dermatological diseases |
| 2015-11-09 | PE0139 | type 2 diabetes mellitus | 2a | PhaseBio Pharmaceuticals (USA - PA) | Metabolic diseases |
| 2015-11-09 | bertilimumab | bullous pemphigoid (BP) | Immune Pharmaceuticals (USA - MA, Israel) | Autoimmune diseases - Dermatological diseases - Rare diseases | |
| 2015-11-09 | bavituximab and immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 | breast cancer, melanoma | preclinical | Peregrine Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-11-09 | cross-reactive antigens against seasonal and pandemic influenza | seasonal and pandemic influenza | Sanofi (France) | Infectious diseases | |
| 2015-11-09 | brontictuzumab (Anti-Notch1, OMP-52M51) | solid tumors | 1 | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-11-09 | brontictuzumab (Anti-Notch1, OMP-52M51) | solid tumors | 1 | Celgene (USA - NJ) | Cancer - Oncology |
